The Scientific Core is designed to successfully recruit and monitor HCV-antibody-negative young injection drug users for HCV infection and to clinically characterize acute infection. Better understanding of spontaneous recovery of HCV infection is necessary to improve methods to prevent and treat chronic infection. A major limitation is the rare recognition of acute infection in humans. We have overcome this obstacle by following persons at risk for HCV infection monthly. By screening for HCV infection and careful monitoring of acutely infected persons, we have established an acute infection repository that has already been used by immunologists to advance our understanding of acute hepatitis C recovery and persistence. For this application, the Core aims to recruit and monitor HCV antibody negative young injection drug users, to clinically characterize acute infection when it occurs, and to establish and maintain an acute infection repository and distribute the resources to NIH funded investigators. By accomplishing these aims, the Clinical Core will make a major contribution to our understanding of hepatitis C recovery and achieve many of the objectives of RFA-AI-09-025. This cohort will allow us to prospectively follow subjects at risk for infection with blood testing including liver enzymes, HCV genotype, and HCV RNA levels and perform serial serum and lymphocyte collection and banking, allowing determination of the timing and outcome of infection and factors associated with outcome. This acute infection repository will distribute its resources for use in projects 1 and 2 as well as to other NIH funded investigators.
The Scientific Core is designed to successfully recruit and monitor young injection drug users who have not yet been exposed to HCV infection. The purpose is to counsel them to avoid infection, but to acquire blood from those who do become infected in order to learn more about how HCV infection evades the immune system and persists.
|Kinchen, Valerie J; Cox, Andrea L; Bailey, Justin R (2018) Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine? Trends Microbiol 26:854-864|
|Esmaeili, Aryan; Mirzazadeh, Ali; Morris, Meghan D et al. (2018) The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative. Clin Infect Dis 66:20-28|
|Kinchen, Valerie J; Zahid, Muhammad N; Flyak, Andrew I et al. (2018) Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. Cell Host Microbe 24:717-730.e5|
|Kinchen, Valerie J; Bailey, Justin R (2018) Defining Breadth of Hepatitis C Virus Neutralization. Front Immunol 9:1703|
|Rose, Rebecca; Lamers, Susanna L; Massaccesi, Guido et al. (2018) Complex patterns of Hepatitis-C virus longitudinal clustering in a high-risk population. Infect Genet Evol 58:77-82|
|Ke, Ruian; Li, Hui; Wang, Shuyi et al. (2018) Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence. Proc Natl Acad Sci U S A 115:E7139-E7148|
|Bailey, Justin R; Barnes, Eleanor; Cox, Andrea L (2018) Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Gastroenterology :|
|Mankowski, Madeleine C; Kinchen, Valerie J; Wasilewski, Lisa N et al. (2018) Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proc Natl Acad Sci U S A 115:E82-E91|
|Morris, Meghan D; Shiboski, Stephen; Bruneau, Julie et al. (2017) Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. Clin Infect Dis 64:860-869|
|Vergara, C; Thio, C; Latanich, R et al. (2017) Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections. Genes Immun 18:82-87|
Showing the most recent 10 out of 59 publications